Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Microbial Contamination Check During Culture in Bioreactor Operations – V 2.0

Posted on By


Biosimilars: SOP for Microbial Contamination Check During Culture in Bioreactor Operations – V 2.0


Standard Operating Procedure for Microbial Contamination Check During Culture in Bioreactor Operations for Biosimilars

Department Biosimilars
SOP No. SOP/BS/079/2025
Supersedes SOP/BS/079/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a standard method for detecting microbial contamination during bioreactor operations in the biosimilar manufacturing process, ensuring timely identification and mitigation in compliance with GMP guidelines.

2. Scope

This SOP applies to all bioreactors (stainless steel and single-use) used for upstream biosimilar production that require routine microbial contamination checks during culture.

3. Responsibilities

  • Process Operators: Collect in-process samples aseptically for microbial testing.
  • Microbiology Analysts: Perform microbial testing, incubation, and reporting.
  • QA Officer: Review reports and initiate CAPA in case of positive results.

4. Accountability

The Microbiology Manager is accountable for ensuring microbial contamination checks are conducted as per this SOP and any deviations are properly documented.

5. Procedure

5.1 Sampling Frequency and Materials

  1. Collect samples once every 24 hours during culture, or as defined in the Batch Manufacturing Record (BMR).
  2. Use sterile syringes or septum ports and sterile sample containers labeled with:
    • Batch No.
    • Date & Time
    • Bioreactor ID

5.2 Sample Collection Procedure

  1. Wipe sampling port with 70% IPA and wear sterile gloves.
  2. Withdraw 5–10 mL of culture fluid using sterile technique.
  3. Transfer immediately to labeled container and send to Microbiology Lab within 30 minutes.
  4. Log collection details in Annexure-1.

5.3 Microbiological Testing

  1. Perform the following tests:
    • Total Aerobic Count (TAMC)
    • Total Yeast and Mold Count (TYMC)
    • Gram Staining
    • Rapid Mycoplasma Detection (if needed)
  2. Inoculate 1 mL sample into TSB and FTM media and incubate at 20–25°C and 30–35°C respectively for 7 days.
  3. Record test results daily for contamination signs (Annexure-2).

5.4 Result Interpretation and Actions

  1. If growth is observed, immediately:
    • Quarantine the bioreactor
    • Collect second confirmatory sample
    • Inform QA and initiate deviation report
  2. If confirmed, terminate batch and initiate CAPA and cleaning validation.
  3. Document all results and corrective measures in Annexure-3.

6. Abbreviations

  • TAMC: Total Aerobic Microbial Count
  • TYMC: Total Yeast and Mold Count
  • CAPA: Corrective and Preventive Action
  • IPA: Isopropyl Alcohol

7. Documents

  1. Sampling Log – Annexure-1
  2. Microbial Test Observation Log – Annexure-2
  3. Deviation and CAPA Record – Annexure-3

8. References

  • USP <61> and <62> – Microbiological Examination
  • WHO TRS 1004 – GMP for Biotech Products
  • ICH Q9 – Quality Risk Management

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Sampling Log

Date Time Batch No. Reactor ID Collected By Remarks
04/05/2025 09:00 BS-079-B01 BR-03 Rajesh Kumar Normal

Annexure-2: Microbial Test Observation Log

Date Media Type Incubation Temp Observation Analyst
04/05/2025 TSB 30–35°C No Growth Sunita Reddy

Annexure-3: Deviation and CAPA Record

Date Deviation Description Immediate Action CAPA QA Review
04/05/2025 Positive Bacterial Growth Batch Hold Re-training & Sanitation Pending

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added rapid detection method and Annexure-3 CAPA record Compliance Upgrade
See also  Biosimilars: SOP for Cell Line Authentication - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Elixir Department: SOP for Line Clearance Before Manufacturing – V 2.0
Next Post: API Manufacturing: SOP for Analytical Method Transfer to QC – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version